January 30, 2025 | FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

On January 30, 2025, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets — a first-in-class non-opioid analgesic — for the treatment of moderate to severe acute pain in adults.

Pain is a common medical condition, and relieving pain is a key therapeutic goal. Acute pain refers to short-term pain, typically caused by some form of tissue injury such as trauma or surgery. It is often treated with analgesics, which may or may not contain opioids.

The U.S. FDA has long supported the development of non-opioid analgesics, primarily to address the severe opioid abuse crisis by reducing opioid prescriptions and overdose deaths, while filling the treatment gap for moderate-to-severe acute pain and providing patients with safer, low-addiction treatment options.

Suzetrigine

 Suzetrigine Starting Materials and Intermediates

RELYBO is committed to providing global customers with high-purity, high-quality  Suzetrigine intermediates with stable supply from kilogram to ton cales, accelerating the innovation and commercialization of oral GLP-1 therapies.